Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Farías, Eduardo; Ranuncolo, Stella Maris; Cresta, Carlos; Specterman, Sergio; Armanasco, Eduardo; Varela, Mirta; Lastiri, José; Pallotta, María Guadalupe; Joffé, Elisa Bal de Kier; Puricelli, Lydia

doi:10.1002/1097-0215(20000720)89:4<389::aid-ijc12>3.0.co;2-j

Cited by 51 publications

(52 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the bloodstream extracellular DNA are under the pressure of factors influencing its circulation and clearance, including hydrolysing enzymes. It is known that tumour invasion in cancer patients is accompanied by increased level of proteases (Farias et al, 2000). Damage of the cellsurface DNA-binding proteins by these enzymes can result in detachment of cell-bound DNA.…”

Section: Discussionmentioning

confidence: 99%

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

et al. 2006

View full text Add to dashboard Cite

Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA. Concentration of cirDNA and methylation of RARb2, RASSF1A and HIC-1 gene promoters were investigated in cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma. Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surfacebound fractions. Analysis of RARb2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women. Results of the study indicate that methylation-specific PCR of RARb2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

et al. 2006

View full text Add to dashboard Cite

show abstract

“…This finding indicates that the cirNA concentration in plasma is determined not only by the intensity of cell death (12 ) or by active secretion from cells (13 ) but also by the interaction of cirNAs with cell surface and plasma biopolymers. Increased concentrations of proteases accompanying tumor invasion in cancer patients (14,15 ) can cause damage to the cell-surface NA-binding proteins and detachment of the cell-surface-bound cirNAs. Proteolytic enzymes are also responsible for endometrium turnover in the uterus (16 ), and background protease activity combined with known high nuclease activity in blood plasma (17 ) can affect the concentrations and distribution of cirNAs in the blood of healthy female donors and sick female patients.…”

Section: Quality Specifications Formentioning

confidence: 99%

Limited Additional Release of Cardiac Troponin I and T in Isoproterenol-Treated Beagle Dogs with Cardiac Injury

Feng¹,

Taggart

Hall

et al. 2005

Clinical Chemistry

View full text Add to dashboard Cite

“…So they tought that MMP-9 le vels might ha ve a prog nos tic va lu e. 24 In ot her stu di es, the re was no re la ti ons hip bet we en the se pa ra me ters and tu mor sta ge or metas ta sis. 9,11,12 In the study of La ack et al, the pret re at ment se rum le vel of MMP-9 was iden ti fi ed as an in depen dent prog nos tic fac tor and had a hig her prognos tic re le van ce than that of VEGF. 3 In most pub lis hed stu di es, se rum VEGF le vel has no prognos tic va lu e on sur vi val.…”

Section: Discussionmentioning

confidence: 99%

The Role of Serum Adhesion Molecules and Vascular Endothelial Growth Factor in Lung Cancer Patients

Yurdakul¹,

Han²,

Bukan³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) which are involved in anjiogenesis and serum intercellular adhesion molecule (sICAM) which is a transmembranous protein from the immunoglobulin family play important role in tumor progression. The aim of this study was to analyze the association of serum levels of MMP-9, MMP-13, VEGF and sICAM with clinical parameters and survival in patients with non-small-cell lung cancer (NSCLC), and to determine whether these proteins might be useful tumor markers for lung cancer. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : In our study, serum levels of MMP-9, MMP-13, VEGF and sICAM were analysed in 72 patients with NSCLC patients (mean age: 60.03±10.86) and 46 healthy controls (mean age: 61.13 ± 14.71). The analysis was performed by enyzme-linked immunosorbent assay (ELISA). R Re es su ul lt ts s: : The median survival of all patients was 22 months. Serum levels of sICAM, VEGF and MMP-9 were increased in NSCLC patients (985 ± 489.4, 248.7±255.9, 5148.2±1996.2) compared with the healthy controls (300.5 ± 204.1, 182.1 ± 207.5, 2943.6 ± 851.7), whereas MMP-13 levels were not significantly different from healthy control group (0.46 ± 0.48, 0.53 ± 1.35) (p> 0.05). No statistically significant relationships were found between all investigated serum parameters and age, smoking, Eastern Cooperative Oncology Group performance status, or gender (p> 0.05). Additionally, there was no significant association between all serum parameters levels and survival in NSCLC patients (p> 0.05). C Co on nc cl lu us si io on n: : High levels of MMP-9, VEGF and sICAM were found in NSCLC patients, however there was no statistically significance in MMP-13 levels. Analysis of serum levels of MMP-9, VEGF and sICAM appears as a potential tumor marker. K Ke ey y W Wo or rd ds s: : Vascular endothelial growth factors; lung; matrix metalloproteinases; intercellular adhesion molecule-1 Ö ÖZ ZE ET T A Am ma aç ç: : Anjiogenezis içinde yer alan matriks metalloproteinaz (MMP) ile vasküler endotelyal büyüme faktörü (VEGF) ve immunglogulin ailesi içinde yer alan transmembranöz bir protein olan dolaşımdaki intersellüler adezyon molekülleri (sICAM) tümör progresyonunda önemli rol oynar. Bu çalışmanın amacı, küçük hücreli dışı akciğer kanserli (KHDAK) hastalarda tedavi öncesi ölçülen MMP-9, MMP-13, VEGF ve sICAM serum düzeyleri ile hastaların klinik parametreleri ve yaşam süreleri arasındaki ilişkiyi analiz etmektir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmamızda 72 KHDAK'li hasta (ort. yaş: 60.03 ± 10.86) ile 46 sağlıklı kontrol grubunda (ort. yaş: 61.13 ± 14.71) MMP-9, MMP-13, VEGF ve sICAM serum düzeyleri analiz edildi. Analizler ELİSA yöntemi ile yapıldı. B Bu ul lg gu ul la ar r: : KHDAK'li hastaların medyan yaşam süresi 22 ay olarak bulundu. MMP-9, VEGF ve sICAM serum seviyeleri sağlıklı kontrol grubu (300.5 ± 204.1, 182.1 ± 207.5, 2943.6 ± 851.7) ile karşılaştırıldığında, KHDAK'li hastalarda ...

show abstract

Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Cited by 51 publications

References 18 publications

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

Limited Additional Release of Cardiac Troponin I and T in Isoproterenol-Treated Beagle Dogs with Cardiac Injury

The Role of Serum Adhesion Molecules and Vascular Endothelial Growth Factor in Lung Cancer Patients

Contact Info

Product

Resources

About